ReviewMuscle & nerve2016
ALS biomarkers for therapy development: State of the field and future directions.
Review in Muscle & nerve, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
56 citing papers in PubMed.
- Longitudinal plasma proteomics predict phenoconversion to clinically manifest ALS.Nature medicine · 2026Article
- Skeletal Muscle Biomarkers of Amyotrophic Lateral Sclerosis: A Large-Scale, Multi-Cohort Proteomic Study.Annals of neurology · 2026Article
- Predicting Phenoconversion to Clinically Manifest ALS: Results of a Large-Scale Proteomic Study.medRxiv : the preprint server for health sciences · 2025Article
- IsomiR Utility in Amyotrophic Lateral Sclerosis Prognostication.medRxiv : the preprint server for health sciences · 2025Article
- The myokine FGF21 associates with enhanced survival in ALS and mitigates stress-induced cytotoxicity.Aging · 2025Article
- Diagnostic potential of urinary CX3CL1 for amnestic mild cognitive impairment and Alzheimer's disease.Frontiers in aging neuroscience · 2025Article
- CK1δ/ε-mediated TDP-43 phosphorylation contributes to early motor neuron disease toxicity in amyotrophic lateral sclerosis.Acta neuropathologica communications · 2024Article
- Prognostic Clinical and Biological Markers for Amyotrophic Lateral Sclerosis Disease Progression: Validation and Implications for Clinical Trial Design and Analysis.medRxiv : the preprint server for health sciences · 2024Article
- The relationship of rate and pause features to the communicative participation of people living with ALS.Muscle & nerve · 2024Article
- Amyotrophic lateral sclerosis stratification: unveiling patterns with virome, inflammation, and metabolism molecules.Journal of neurology · 2024Article
- Evaluation of the Safety and Efficacy of Repeated Mesenchymal Stem Cell Transplantations in ALS Patients by Investigating Patients' Specific Immunological and Biochemical Biomarkers.Diseases (Basel, Switzerland) · 2024Article
- Skeletal muscle as a molecular and cellular biomarker of disease progression in amyotrophic lateral sclerosis: a narrative review.Neural regeneration research · 2024Review
- Biomarker Qualification for Neurofilament Light Chain in Amyotrophic Lateral Sclerosis: Theory and Practice.Annals of neurology · 2024Review
- Neurofilament light chain: a biomarker at the crossroads of clarity and confusion for gene-directed therapies.Neurodegenerative disease management · 2024Review
- A comprehensive review of electrophysiological techniques in amyotrophic lateral sclerosis research.Frontiers in cellular neuroscience · 2024Review
- Protein Citrullination in Amyotrophic Lateral Sclerosis and Other Neurodegenerative Diseases.Journal of experimental neurology · 2024Article
- Advances in molecular pathology, diagnosis, and treatment of amyotrophic lateral sclerosis.BMJ (Clinical research ed.) · 2023Review
- Neurofilament light chain in drug development for amyotrophic lateral sclerosis: a critical appraisal.Brain : a journal of neurology · 2023Article
- Review
- Urinary neopterin: A novel biomarker of disease progression in amyotrophic lateral sclerosis.European journal of neurology · 2022Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Biomarkers have become the focus of intense research in the field of amyotrophic lateral sclerosis (ALS), with the hope that they might aid therapy development efforts. Notwithstanding the discovery of many candidate biomarkers, none have yet emerged as validated tools for drug development. In this review we present a nuanced view of biomarkers based on the perspective of the Food and Drug Administration; highlight the distinction between discovery and validation; describe existing and emerging resources; review leading biological fluid-based, electrophysiological, and neuroimaging candidates relevant to therapy development efforts; discuss lessons learned from biomarker initiatives in related neurodegenerative diseases; and outline specific steps that we, as a field, might take to hasten the development and validation of biomarkers that will prove useful in enhancing efforts to develop effective treatments for ALS patients. Most important among these is the proposal to establish a federated ALS Biomarker Consortium in which all interested and willing stakeholders may participate with equal opportunity to contribute to the broader mission of biomarker development and validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.